| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $30.1M | — | -19.7% |
| SG&A Expense | $11.3M | — | +13.2% |
| Operating Income | -$41.4M | — | +12.7% |
| Net Income | -$39.7M | — | +11.0% |
| EPS (Basic) | -$0.66 | — | +35.9% |
| EPS (Diluted) | -$0.66 | — | +35.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $32.2M | -74.1% | -43.4% |
| Short-term Investments | $204.3M | +31.6% | +9.9% |
| Current Assets | $241.7M | -14.6% | -2.4% |
| Total Assets | $257.0M | -12.5% | -1.4% |
| Current Liabilities | $29.7M | -18.7% | -10.9% |
| Total Liabilities | $61.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$41.6M | — | +7.4% |
| Investing Cash Flow | -$50.2M | — | -1000.0% |
| Financing Cash Flow | -$101K | — | +75.6% |
| +67.7% |
| Stockholders' Equity | $195.6M | -15.8% | -12.7% |